Pharmacology and therapeutic potential of pattern recognition receptors

Pharmacology and Therapeutics

Volumn 135, Issue 2, 2012, Pages 200-215

  Paul Clark, M J ^a   George, P M ^a   Gatheral, T ^a   Parzych, K ^a   Wright, W R ^a   Crawford, D ^a   Bailey, L K ^a   Reed, D M ^a   Mitchell, J A ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Inflammation; Innate immunity; LPS; Pathogen associated molecular patterns; Pattern recognition receptors; Toll like receptors

Indexed keywords

LIPOPOLYSACCHARIDE; PATTERN RECOGNITION RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; ZYMOSAN;

HUMAN; INFLAMMATION; NONHUMAN; PATHOGEN ASSOCIATED MOLECULAR PATTERN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW;

ANIMALS; HUMANS; INFLAMMATION; RECEPTORS, PATTERN RECOGNITION; TOLL-LIKE RECEPTORS;

EID: 84862703251     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2012.05.007     Document Type: Review

References (291)

1. Agrawal, S., & Kandimalla, E. R. (2007). Synthetic agonists of Toll-like receptors 7, 8 and 9. Biochem Soc Trans 35, 1461-1467.
2. Ahmad-Nejad, P., Mrabet-Dahbi, S., Breuer, K., Klotz, M., Werfel, T., Herz, U., et al. (2004). The Toll-like receptor 2 R753Q polymorphismdefines a subgroup of patients with atopic dermatitis having severe phenotype. J Allergy Clin Immunol 113, 565-567.
3. Aksentijevich, I., C.D., Putnam, Remmers, E. F., Mueller, J. L., Le, J., Kolodner, R. D., et al. (2007). The clinical continuum of cryopyrinopathies: novel CIAS1 mutations in North American patients and a new cryopyrinmodel. Arthritis Rheum 56, 1273-1285.
4. Alnemri, E. S. (2010). Sensing cytoplasmic danger signals by the inflammasome. J Clin Immunol 30, 512-519.
5. Amer, A., Franchi, L., Kanneganti, T. D., Body-Malapel, M., Ozoren, N., Brady, G., et al. (2006). Regulation of Legionella phagosome maturation and infection through flagellin and host Ipaf. J Biol Chem 281, 35217-35223.
6. Anderson, K. V., Bokla, L., & Nusslein-Volhard, C. (1985). Establishment of dorsal-ventral polarity in the Drosophila embryo: the induction of polarity by the Toll gene product. Cell 42, 791-798.
7. Andre, F., Slimane, K., Bachelot, T., Dunant, A., Namer, M., Barrelier, A., et al. (2004). Breast cancer with synchronous metastases: trends in survival during a 14-year period. J Clin Oncol 22, 3302-3308.
8. Arbour, N. C., Lorenz, E., Schutte, B. C., Zabner, J., Kline, J. N., Jones, M., et al. (2000). TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 25, 187-191.
9. Avril, T., de Tayrac, M., Leberre, C., & Quillien, V. (2009). Not all polyriboinosinic-polyribocytidylic acids (Poly I:C) are equivalent for inducing maturation of dendritic cells: implication for alpha-type-1 polarized DCs. J Immunother 32, 353-362.
10. Babelova, A., Moreth, K., Tsalastra-Greul, W., Zeng-Brouwers, J., Eickelberg, O., Young, M. F., et al. (2009). Biglycan, a danger signal that activates the NLRP3 inflammasome via Toll-like and P2X receptors. J Biol Chem 284, 24035-24048.
11. Belichard, P., Landry, M., Faye, P., Bachvarov, D. R., Bouthillier, J., Pruneau, D., et al. (2000). Inflammatory hyperalgesia induced by zymosan in the plantar tissue of the rat: effect of kinin receptor antagonists. Immunopharmacology 46, 139-147.
12. Berdeli, A., Celik, H. A., Ozyurek, R., Dogrusoz, B., & Aydin, H. H. (2005). TLR-2 gene Arg753Gln polymorphism is strongly associated with acute rheumatic fever in children. J Mol Med 83, 535-541.
13. Bianchi, R., Adami, C., Giambanco, I., & Donato, R. (2007). S100B binding to RAGE in microglia stimulates COX-2 expression. J Leukoc Biol 81, 108-118.
14. Bishop-Bailey, D., Larkin, S. W., Warner, T. D., Chen, G., & Mitchell, J. A. (1997). Characterization of the induction of nitric oxide synthase and cyclo-oxygenase in rat aorta in organ culture. Br J Pharmacol 121, 125-133.
15. Bohnhorst, J., Rasmussen, T., Moen, S. H., Flottum, M., Knudsen, L., Borset, M., et al. (2006). Toll-like receptors mediate proliferation and survival of multiple myeloma cells. Leukemia 20, 1138-1144.
16. Boonstra, A., Asselin-Paturel, C., Gilliet, M., Crain, C., Trinchieri, G., Liu, Y. J., et al. (2003). Flexibility of mouse classical and plasmacytoid-derived dendritic cells in directing T helper type 1 and 2 cell development: dependency on antigen dose and differential Toll-like receptor ligation. J Exp Med 197, 101-109.
17. Boraska Jelavic, T., Barisic, M., Drmic Hofman, I., Boraska, V., Vrdoljak, E., Peruzovic, M., et al. (2006). Microsatellite GT polymorphism in the Toll-like receptor 2 is associated with colorectal cancer. Clin Genet 70, 156-160.
18. Brade, V., & Vogt, W. (1971). Anaphylatoxin formation by contact activation of plasma. II. Implication of properdin and an unknown plasma factor in activation by zymosan. Eur J Immunol 1, 295-300.
19. Brown, G. D., Herre, J., Williams, D. L., Willment, J. A., Marshall, A. S., & Gordon, S. (2003). Dectin-1 mediates the biological effects of beta-glucans. J Exp Med 197, 1119-1124.
20. Bryant, C., & Fitzgerald, K. A. (2009). Molecular mechanisms involved in inflammasome activation. Trends Cell Biol 19, 455-464.
21. Bujak, M., & Frangogiannis, N. G. (2009). The role of IL-1 in the pathogenesis of heart disease. Arch Immunol Ther Exp (Warsz) 57, 165-176.
22. Burger-Kentischer, A., Abele, I. S., Finkelmeier, D., Wiesmuller, K. H., & Rupp, S. (2010). A new cell-based innate immune receptor assay for the examination of receptor activity, ligand specificity, signalling pathways and the detection of pyrogens. J Immunol Methods 358(1-2), 93-103.
23. Calvano, S. E., Thompson, W. A., Marra, M. N., Coyle, S. M., de Riesthal, H. F., Trousdale, R. K., et al. (1994). Changes in polymorphonuclear leukocyte surface and plasma bactericidal/permeability-increasing protein and plasma lipopolysaccharide binding protein during endotoxemia or sepsis. Arch Surg 129, 220-226.
24. Camhi, S. L., Alam, J., Otterbein, L., Sylvester, S. L., & Choi, A. M. (1995). Induction of heme oxygenase-1 gene expression by lipopolysaccharide is mediated by AP-1 activation. Am J Respir Cell Mol Biol 13, 387-398.
25. Cartwright, N., McMaster, S. K., Sorrentino, R., Paul-Clark, M., Sriskandan, S., Ryffel, B., et al. (2007a). Elucidation of Toll-like receptor and adapter protein signaling in vascular dysfunction induced by gram-positive Staphylococcus aureus or gram-negative Escherichia coli. Shock 27, 40-47.
26. Cartwright, N., Murch, O., McMaster, S. K., Paul-Clark, M. J., van Heel, D. A., Ryffel, B., et al. (2007b). Selective NOD1 agonists cause shock and organ injury/dysfunction in vivo. Am J Respir Crit Care Med 175, 595-603.
27. Chakrabarti, D., Hultgren, B., & Stewart, T. A. (1996). IFN-alpha induces autoimmune T cells through the induction of intracellular adhesionmolecule-1 and B7.2. J Immunol 157, 522-528.
28. Chamaillard, M., Hashimoto, M., Horie, Y., Masumoto, J., Qiu, S., Saab, L., et al. (2003a). An essential role for NOD1 in host recognition of bacterial peptidoglycan containing diaminopimelic acid. Nat Immunol 4, 702-707.
29. Chamaillard, M., Philpott, D., Girardin, S. E., Zouali, H., Lesage, S., Chareyre, F., et al. (2003b). Gene-environment interaction modulated by allelic heterogeneity in inflammatory diseases. Proc Natl Acad Sci U S A 100, 3455-3460.
30. Chamberlain, J., Francis, S., Brookes, Z., Shaw, G., Graham, D., Alp, N. J., et al. (2009). Interleukin-1 regulates multiple atherogenic mechanisms in response to fat feeding. PLoS One 4, e5073.
31. Chatterjee, B. E., Yona, S., Rosignoli, G., Young, R. E., Nourshargh, S., Flower, R. J., et al. (2005). Annexin 1-deficient neutrophils exhibit enhanced transmigration in vivo and increased responsiveness in vitro. J Leukoc Biol 78, 639-646.
32. Chauhan, V. S., Sterka, D. G., Jr., Furr, S. R., Young, A. B., & Marriott, I. (2009). NOD2 plays an important role in the inflammatory responses of microglia and astrocytes to bacterial CNS pathogens. Glia 57, 414-423.
33. Chedid, L. A., Parant, M. A., Audibert, F. M., Riveau, G. J., Parant, F. J., Lederer, E., et al. (1982). Biological activity of a new synthetic muramyl peptide adjuvant devoid of pyrogenicity. Infect Immun 35, 417-424.
34. Chen, M. C., Chen, C. J., Yang, C. H., Wu, C. J., Fang, C. Y., Hsieh, Y. K., et al. (2007). Interleukin-18: a strong predictor of the extent of coronary artery disease in patients with unstable angina. Heart Vessels 22, 371-375.
35. Chiang, D. J., Ye, Y. L., Chen, W. L., Lee, Y. L., Hsu, N. Y., & Chiang, B. L. (2003). Ribavirin or CpG DNA sequence-modulated dendritic cells decrease the IgE level and airway inflammation. Am J Respir Crit Care Med 168, 575-580.
36. Conlon, K. C., Urba, W. J., Smith, J. W., II, Steis, R. G., Longo, D. L., & Clark, J. W. (1990). Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy. Cancer 65, 2237-2242.
37. Cooper, C. L., Davis, H. L., Angel, J. B., Morris, M. L., Elfer, S. M., Seguin, I., et al. (2005). CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults. AIDS 19, 1473-1479.
38. Cornet, S., Menez-Jamet, J., Lemonnier, F., Kosmatopoulos, K., & Miconnet, I. (2006). CpG oligodeoxynucleotides activate dendritic cells in vivo and induce a functional and protective vaccine immunity against a TERT derived modified cryptic MHC class I-restricted epitope. Vaccine 24, 1880-1888.
39. Cox, J. C., & Coulter, A. R. (1997). Adjuvants-a classification and review of their modes of action. Vaccine 15, 248-256.
40. Cuzzocrea, S., Costantino, G., Zingarelli, B., & Caputi, A. P. (1999). Protective effects of poly (ADP-ribose) synthase inhibitors in zymosan-activated plasma induced paw edema. Life Sci 65, 957-964.
41. Cuzzocrea, S., Zingarelli, B., Sautebin, L., Rizzo, A., Crisafulli, C., Campo, G. M., et al. (1997). Multiple organ failure following zymosan-induced peritonitis is mediated by nitric oxide. Shock 8, 268-275.
42. da Silva Correia, J., Soldau, K., Christen, U., Tobias, P. S., & Ulevitch, R. J. (2001). Lipopolysaccharide is in close proximity to each of the proteins in its membrane receptor complex. Transfer from CD14 to TLR4 and MD-2. J Biol Chem 276, 21129-21135.
43. Darcissac, E. C., Truong,M. J.,Dewulf, J.,Mouton, Y., Capron, A., & Bahr, G.M. (2000). The synthetic immunomodulator murabutide controls human immunodeficiency virus type 1 replication atmultiple levels inmacrophages and dendritic cells. J Virol 74, 7794-7802.
44. Darveau, R. P., Pham, T. T., Lemley, K., Reife, R. A., Bainbridge, B. W., Coats, S. R., et al. (2004). Porphyromonas gingivalis lipopolysaccharide contains multiple lipid A species that functionally interact with both Toll-like receptors 2 and 4. Infect Immun 72, 5041-5051.
45. Davis, H. L., Weeratna, R., Waldschmidt, T. J., Tygrett, L., Schorr, J., & Krieg, A. M. (1998). CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J Immunol 160, 870-876.
46. DeForge, L. E., Kenney, J. S., Jones, M. L., Warren, J. S., & Remick, D. G. (1992). Biphasic production of IL-8 in lipopolysaccharide (LPS)-stimulated human whole blood. Separation of LPS- and cytokine-stimulated components using anti-tumor necrosis factor and anti-IL-1 antibodies. J Immunol 148, 2133-2141.
47. Demling, R., Lalonde, C., Youn, Y. K., Daryani, R., Campbell, C., & Knox, J. (1992). Lung oxidant changes after zymosan peritonitis: relationship between physiologic and biochemical changes. Am Rev Respir Dis 146, 1272-1278.
48. Derkx, B., Wittes, J., & McCloskey, R. (1999). Randomized, placebo-controlled trial of HA-1A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock. European Pediatric Meningococcal Septic Shock Trial Study Group. Clin Infect Dis 28, 770-777.
49. Diebold, S. S., Kaisho, T., Hemmi, H., Akira, S., & Reis e Sousa, C. (2004). Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303, 1529-1531.
50. Diebold, S. S., Schulz, O., Alexopoulou, L., Leitner, W. W., Flavell, R. A., & Reis e Sousa, C. (2009). Role of TLR3 in the immunogenicity of replicon plasmid-based vaccines. Gene Ther 16, 359-366.
51. Dietrich, N., Lienenklaus, S., Weiss, S., & Gekara, N. O. (2010). Murine Toll-like receptor 2 activation induces type I interferon responses from endolysosomal compartments. PLoS One 5, e10250.
52. Dinarello, C. A. (1996). Biologic basis for interleukin-1 in disease. Blood 87, 2095-2147.
53. Dostert, C., Petrilli, V., Van Bruggen, R., Steele, C., Mossman, B. T., & Tschopp, J. (2008). Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 320, 674-677.
54. Doz, E., Noulin, N., Biochot, E., Guénon, I., Flick, L., Le Bert, M., et al. (2008). Cigarette smoke-induced pulmonary inflammation is TLR4/MyD88 and IL-1R/MyD88 signaling dependent. J Immunol 180, 1169-1178.
55. Drickamer, K., & Dodd, R. B. (1999). C-type lectin-like domains in Caenorhabditis elegans: predictions from the complete genome sequence. Glycobiology 9, 1357-1369.
56. Duewell, P., Kono, H., Rayner, K. J., Sirois, C. M., Vladimer, G., Bauernfeind, F. G., et al. (2010). NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464, 1357-1361.
57. Eder, C. (2009). Mechanisms of interleukin-1beta release. Immunobiology 214(7), 543-553.
58. Eder, W., Klimecki, W., Yu, L., von Mutius, E., Riedler, J., Braun-Fahrlander, C., et al. (2004). Toll-like receptor 2 as a major gene for asthma in children of European farmers. J Allergy Clin Immunol 113, 482-488.
59. Eisenbarth, S. C., Colegio, O. R., O'Connor, W., Sutterwala, F. S., & Flavell, R. A. (2008). Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 453, 1122-1126.
60. Eisenbarth, S. C., & Flavell, R. A. (2009). Innate instruction of adaptive immunity revisited: the inflammasome. EMBO Mol Med 1, 92-98.
61. Eltom, S., Stevenson, C. S., Rasterick, J., Dale, N., Raemdonck, K., Wong, S., et al. (2011). P2X7receptor and caspase 1 activation are central to airway inflammation observed after exposure to tobacco smoke. PLoS One 6, e24097.
62. Espinola-Klein, C., Rupprecht, H. J., Blankenberg, S., Bickel, C., Kopp, H., Victor, A., et al. (2002). Impact of infectious burden on progression of carotid atherosclerosis. Stroke 33, 2581-2586.
63. Fearon, D. T., & Austen, K. F. (1977). Activation of the alternative complement pathway due to resistance of zymosan-bound. Proc Natl Acad Sci U S A 74, 1683-1687.
64. Fernandes-Alnemri, T., Yu, J. W., Datta, P., Wu, J., & Alnemri, E. S. (2009). AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA. Nature 458, 509-513.
65. Ferwerda, B., McCall, M. B., Verheijen, K., Kullberg, B. J., van der Ven, A. J., Van der Meer, J. W., et al. (2008). Functional consequences of Toll-like receptor 4 polymorphisms. Mol Med 14, 346-352.
66. Figdor, C. G., van Kooyk, Y., & Adema, G. J. (2002). C-type lectin receptors on dendritic cells and Langerhans cells. Nat Rev Immunol 2, 77-84.
67. Foell, D.,Wittkowski, H., Vogl, T., & Roth, J. (2007). S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. J Leukoc Biol 81, 28-37.
68. Foldes, G., Liu, A., Badiger, R., Paul-Clark, M., Moreno, L., Lendvai, Z., et al. (2010). Innate immunity in human embryonic stem cells: comparison with adult human endothelial cells. PLoS One 5, e10501.
69. Frantz, S., Kelly, R. A., & Bourcier, T. (2001). Role of TLR-2 in the activation of nuclear factor kappaB by oxidative stress in cardiac myocytes. J Biol Chem 276, 5197-5203.
70. Frostegard, J., Ulfgren, A. K., Nyberg, P., Hedin, U., Swedenborg, J., Andersson, U., et al. (1999). Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis 145, 33-43.
71. Gallay, P., Barras, C., Tobias, P. S., Calandra, T., Glauser, M. P., & Heumann, D. (1994). Lipopolysaccharide (LPS)-binding protein in human serum determines the tumor necrosis factor response of monocytes to LPS. J Infect Dis 170, 1319-1322.
72. Galuppo, M., Di Paola, R., Mazzon, E., Genovese, T., Crisafulli, C., Paterniti, I., et al. (2010). Role of PPAR-delta in the development of zymosan-induced multiple organ failure: an experiment mice study. J Inflamm (Lond) 7, 12.
73. Gans, K. R., Lundy, S. R., Dowling, R. L., Stevens, T. M., & Kerr, J. S. (1989). Extracellular phospholipase A2 activity in cell free peritoneal lavage fluid frommicewith zymosan peritonitis. Agents Actions 27, 341-343.
74. Gantner, B. N., Simmons, R. M., Canavera, S. J., Akira, S., & Underhill, D. M. (2003). Collaborative induction of inflammatory responses by dectin-1 and Toll-like receptor 2. J Exp Med 197, 1107-1117.
75. Garantziotis, S., Li, Z., Potts, E. N., Lindsey, J. Y., Stober, V. P., Polosukhin, V. V., et al. (2010). TLR4 is necessary for hyaluronan-mediated airway hyperresponsiveness after ozone inhalation. Am J Respir Crit Care Med 181, 666-675.
76. Gay, N. J., & Keith, F. J. (1991). Drosophila Toll and IL-1 receptor. Nature 351, 355-356.
77. Geddes, K., Magalhaes, J. G., & Girardin, S. E. (2009). Unleashing the therapeutic potential of NOD-like receptors. Nat Rev Drug Discov 8, 465-479.
78. Geijtenbeek, T. B., Krooshoop, D. J., Bleijs, D. A., van Vliet, S. J., van Duijnhoven, G. C., Grabovsky, V., et al. (2000a). DC-SIGN-ICAM-2 interaction mediates dendritic cell trafficking. Nat Immunol 1, 353-357.
79. Geijtenbeek, T. B., Kwon, D. S., Torensma, R., van Vliet, S. J., van Duijnhoven, G. C., Middel, J., et al. (2000b). DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 100, 587-597.
80. Gerdes, N., Sukhova, G. K., Libby, P., Reynolds, R. S., Young, J. L., & Schonbeck, U. (2002). Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for atherogenesis. J Exp Med 195, 245-257.
81. Getting, S. J., Flower, R. J., & Perretti,M. (1997). Inhibition of neutrophil andmonocyte recruitment by endogenous and exogenous lipocortin 1. Br J Pharmacol 120, 1075-1082.
82. Gewirtz, A. T. (2007). TLRs in the gut. III. Immune responses to flagellin in Crohn's disease: good, bad, or irrelevant? Am J Physiol Gastrointest Liver Physiol 292, G706-G710.
83. Gewirtz, A. T., Vijay-Kumar, M., Brant, S. R., Duerr, R. H., Nicolae, D. L., & Cho, J. H. (2006). Dominant-negative TLR5 polymorphism reduces adaptive immune response to flagellin and negatively associates with Crohn's disease. Am J Physiol Gastrointest Liver Physiol 290, G1157-G1163.
84. Girardin, S. E., Boneca, I. G., Carneiro, L. A., Antignac, A., Jehanno, M., Viala, J., et al. (2003a). Nod1 detects a unique muropeptide from gram-negative bacterial peptidoglycan. Science 300, 1584-1587.
85. Girardin, S. E., Boneca, I. G., Viala, J., Chamaillard, M., Labigne, A., Thomas, G., et al. (2003b). Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem 278, 8869-8872.
86. Goodridge, H. S., Simmons, R. M., & Underhill, D. M. (2007). Dectin-1 stimulation by Candida albicans yeast or zymosan triggers NFAT activation in macrophages and dendritic cells. J Immunol 178, 3107-3115.
87. Goris, R. J., Boekholtz, W. K., van Bebber, I. P., Nuytinck, J. K., & Schillings, P. H. (1986). Multiple-organ failure and sepsis without bacteria. An experimental model. Arch Surg 121, 897-901.
88. Gotoh, T., Nakahara, K., Iwami, M., Aoki, H., & Imanaka, H. (1982). Studies on a new immunoactive peptide, FK-156. I. Taxonomy of the producing strains. J Antibiot (Tokyo) 35, 1280-1285.
89. Greis, A., Murgott, J., Gerstberger, R., Hubschle, T., & Roth, J. (2009). Effects of repeated injections of fibroblast-stimulating lipopeptide-1 on fever, formation of cytokines, and on the responsiveness to endotoxin in guinea pigs. Acta Physiol (Oxf) 197(1), 35-45.
90. Grube, B. J., Cochane, C. G., Ye, R. D., Green, C. E., McPhail, M. E., Ulevitch, R. J., et al. (1994). Lipopolysaccharide binding protein expression in primary human hepatocytes and HepG2 hepatoma cells. J Biol Chem 269, 8477-8482.
91. Guan, Y., Ranoa, D. R., Jiang, S., Mutha, S. K., Li, X., Baudry, J., et al. (2010). Human TLRs 10 and 1 share common mechanisms of innate immune sensing but not signaling. J Immunol 184, 5094-5103.
92. Guerrero, A. T., Verri, W. A., Jr., Cunha, T. M., Silva, T. A., Schivo, I. R., Dal-Secco, D., et al. (2008). Involvement of LTB4 in zymosan-induced joint nociception in mice: participation of neutrophils and PGE2. J Leukoc Biol 83, 122-130.
93. Guhring, H., Tegeder, I., Lotsch, J., Pahl, A., Werner, U., Reeh, P. W., et al. (2001). Role of nitric oxide in zymosan induced paw inflammation and thermal hyperalgesia. Inflamm Res 50, 83-88.
94. Gursel, M., Verthelyi, D., Gursel, I., Ishii, K. J., & Klinman, D. M. (2002). Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotide. J Leukoc Biol 71, 813-820.
95. Harder, J., Franchi, L.,Munoz-Planillo, R., Park, J. H., Reimer, T., & Nunez, G. (2009). Activation of the Nlrp3 inflammasome by Streptococcus pyogenes requires streptolysin O and NF-kappa B activation but proceeds independently of TLR signaling and P2X7 receptor. J Immunol 183, 5823-5829.
96. Harrington, L. S., Belcher, E., Moreno, L., Carrier, M. J., & Mitchell, J. A. (2007). Homeostatic role of Toll-like receptor 4 in the endothelium and heart. J Cardiovasc Pharmacol Ther 12, 322-326.
97. Hasan, U., Chaffois, C., Gaillard, C., Saulnier, V., Merck, E., Tancredi, S., et al. (2005). Human TLR10 is a functional receptor, expressed by B cells and plasmacytoid dendritic cells, which activates gene transcription through MyD88. J Immunol 174, 2942-2950.
98. Hawn, T. R., Smith, K. D., Aderem, A., & Skerrett, S. J. (2006). Myeloid differentiation primary response gene (88)- and Toll-like receptor 2-deficient mice are susceptible to infection with aerosolized Legionella pneumophila. J Infect Dis 193, 1693-1702.
99. Hawn, T. R.,Verbon,A., Lettinga,K.D., Zhao, L. P., Li, S. S., Laws, R. J., et al. (2003).Acommon dominant TLR5 stop codon polymorphismabolishes flagellin signaling andis associated with susceptibility to legionnaires' disease. J ExpMed 198, 1563-1572.
100. Hawn, T. R., Wu, H., Grossman, J. M., Hahn, B. H., Tsao, B. P., & Aderem, A. (2005). A stop codon polymorphism of Toll-like receptor 5 is associated with resistance to systemic lupus erythematosus. Proc Natl Acad Sci U S A 102, 10593-10597.
101. Hayashi, F., Smith, K. D., Ozinsky, A., Hawn, T. R., Yi, E. C., Goodlett, D. R., et al. (2001). The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 410, 1099-1103.
102. Heil, F., Hemmi, H., Hochrein, H., Ampenberger, F., Kirschning, C., Akira, S., et al. (2004). Species-specific recognition of single-stranded RNA via Toll-like receptor 7 and 8. Science 303, 1526-1529.
103. Hennessy, E. J., Parker, A. E., & O'Neill, L. A. (2010). Targeting Toll-like receptors: emerging therapeutics? Nat Rev Drug Discov 9, 293-307.
104. Hewson, C. A., Jardine, A., Edwards,M. R., Laza-Stanca, V., & Johnston, S. L. (2005). Toll-like receptor 3 is induced by andmediates antiviral activity against rhinovirus infection of human bronchial epithelial cells. J Virol 79, 12273-12279.
105. Hisamatsu, T., Suzuki, M., Reinecker, H. C., Nadeau, W. J., McCormick, B. A., & Podolsky, D. K. (2003). CARD15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells. Gastroenterology 124, 993-1000.
106. Hoebe, K., Georgel, P., Rutschmann, S., Du, X., Mudd, S., Crozat, K., et al. (2005). CD36 is a sensor of diacylglycerides. Nature 433, 523-527.
107. Hornung, V., Ablasser, A., Charrel-Dennis, M., Bauernfeind, F., Horvath, G., Caffrey, D. R., et al. (2009). AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature 458, 514-518.
108. Horsmans, Y., Berg, T., Desager, J. P., Mueller, T., Schott, E., Fletcher, S. P., et al. (2005). Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. Hepatology 42, 724-731.
109. Hoshino, K., Takeuchi, O., Kawai, T., Sanjo, H., Ogawa, T., Takeda, Y., et al. (1999). Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol 162, 3749-3752.
110. Hsu, Y. M., Zhang, Y., You, Y., Wang, D., Li, H., Duramad, O., et al. (2007). The adaptor protein CARD9 is required for innate immune responses to intracellular pathogens. Nat Immunol 8, 198-205.
111. Hugot, J. P., Chamaillard, M., Zouali, H., Lesage, S., Cezard, J. P., Belaiche, J., et al. (2001). Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411, 599-603.
112. Huleatt, J. W., Nakaar, V., Desai, P., Huang, Y., Hewitt, D., Jacobs, A., et al. (2008). Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 26, 201-214.
113. Hunter, J. (2007). A treatise on the blood, inflammation, and gun-shot wounds. 1794. Clin Orthop Relat Res 458, 27-34.
114. Hysi, P., Kabesch, M., Moffatt, M. F., Schedel, M., Carr, D., Zhang, Y., et al. (2005). NOD1 variation, immunoglobulin E and asthma. Hum Mol Genet 14, 935-941.
115. Imamura, M., Tsutsui, H., Yasuda, K., Uchiyama, R., Yumikura-Futatsugi, S., Mitani, K., et al. (2009). Contribution of TIR domain-containing adapter inducing IFN-beta-mediated IL-18 release to LPS-induced liver injury in mice. J Hepatol 51, 333-341.
116. Imler, J. L., & Hoffmann, J. A. (2001). Toll receptors in innate immunity. Trends Cell Biol 11, 304-311.
117. Inohara, N., Ogura, Y., Fontalba, A., Gutierrez, O., Pons, F., Crespo, J., et al. (2003). Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease. J Biol Chem 278, 5509-5512.
118. Ip, W. K., Takahashi, K., Ezekowitz, R. A., & Stuart, L. M. (2009). Mannose-binding lectin and innate immunity. Immunol Rev 230, 9-21.
119. Jack, R. S., Fan, X., Bernheiden, M., Rune, G., Ehlers, M., Weber, A., et al. (1997). Lipopolysaccharide-binding protein is required to combat a murine gram-negative bacterial infection. Nature 389, 742-745.
120. Jain, N. K., Ishikawa, T. O., Spigelman, I., & Herschman, H. R. (2008). COX-2 expression and function in the hyperalgesic response to paw inflammation in mice. Prostaglandins Leukot Essent Fatty Acids 79, 183-190.
121. Jansen, M. J., Hendriks, T., de Man, B. M., van der Meer, J. W., & Goris, R. J. (1999). Interleukin 10 mitigates the development of the zymosan-induced multiple organ dysfunction syndrome in mice. Cytokine 11, 713-721.
122. Jimenez, R., Belcher, E., Sriskandan, S., Lucas, R., McMaster, S., Vojnovic, I., et al. (2005). Role of Toll-like receptors 2 and 4 in the induction of cyclooxygenase-2 in vascular smooth muscle. Proc Natl Acad Sci U S A 102, 4637-4642.
123. Jin, Y., Birlea, S. A., Fain, P. R., & Spritz, R. A. (2007a). Genetic variations in NALP1 are associated with generalized vitiligo in a Romanian population. J Invest Dermatol 127, 2558-2562.
124. Jin, Y., Mailloux, C. M., Gowan, K., Riccardi, S. L., LaBerge, G., Bennett, D. C., et al. (2007b). NALP1 in vitiligo-associated multiple autoimmune disease. N Engl J Med 356, 1216-1225.
125. Johnson, C. M., Lyle, E. A., Omueti, K. O., Stepensky, V. A., Yegin, O., Alpsoy, E., et al. (2007). Cutting edge: a common polymorphismimpairs cell surface trafficking and functional responses of TLR1 but protects against leprosy. J Immunol 178, 7520-7524.
126. Jordens, R., Thompson, A., Amons, R., & Koning, F. (1999). Human dendritic cells shed a functional, soluble form of the mannose receptor. Int Immunol 11, 1775-1780.
127. Kalliolias, G. D., & Liossis, S. N. (2008). The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still's disease and systemiconset juvenile idiopathic arthritis. Expert Opin Investig Drugs 17, 349-359.
128. Karimi, K., Sarir, H., Mortaz, E., Smit, J. J., Hosseini, H., De Kimpe, S. J., et al. (2006). Toll-like receptor-4 mediates cigarette smoke-induced cytokine production by human macrophages. Respir Res 7, 66.
129. Karpala, A. J., Doran, T. J., & Bean, A. G. (2005). Immune responses to dsRNA: implications for gene silencing technologies. Immunol Cell Biol 83, 211-216.
130. Kawasaki, N., Kawasaki, T., & Yamashina, I. (1983). Isolation and characterization of a mannan-binding protein from human serum. J Biochem 94, 937-947.
131. Kelly, M. M., McNagny, K., Williams, D. L., van Rooijen, N., Maxwell, L., Gwozd, C., et al. (2008). The lung responds to zymosan in a unique manner independent of Toll-like receptors, complement, and dectin-1. Am J Respir Cell Mol Biol 38, 227-238.
132. Kern, J. A., Lamb, R. J., Reed, J. C., Daniele, R. P., & Nowell, P. C. (1988). Dexamethasone inhibition of interleukin 1 beta production by human monocytes. Posttranscriptional mechanisms. J Clin Invest 81, 237-244.
133. Kirii, H., Niwa, T., Yamada, Y., Wada, H., Saito, K., Iwakura, Y., et al. (2003). Lack of interleukin-1beta decreases the severity of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 23, 656-660.
134. Kleeberger, S. R., Reddy, S., Zhang, L. Y., & Jedlicka, A. E. (2000). Genetic susceptibility to ozone-induced lung hyperpermeability: role of Toll-like receptor 4. Am J Respir Cell Mol Biol 22, 620-627.
135. Kleinman, M. E., Yamada, K., Takeda, A., Chandrasekaran, V., Nozaki, M., Baffi, J. Z., et al. (2008). Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 452, 591-597.
136. Kodama, T., Reddy, P., Kishimoto, C., & Krieger, M. (1988). Purification and characterization of a bovine acetyl low density lipoprotein receptor. Proc Natl Acad Sci U S A 85, 9238-9242.
137. Kolaczkowska, E., Arnold, B., & Opdenakker, G. (2008). Gelatinase B/MMP-9 as an inflammatory marker enzyme in mouse zymosan peritonitis: comparison of phase-specific and cell-specific production by mast cells, macrophages and neutrophils. Immunobiology 213, 109-124.
138. Kormann, M. S., Depner, M., Hartl, D., Klopp, N., Illig, T., Adamski, J., et al. (2008). Toll-like receptor heterodimer variants protect from childhood asthma. J Allergy Clin Immunol 122, 86-92 (92 e81-88).
139. Krieger, M., & Herz, J. (1994). Structures and functions of multiligand lipoprotein receptors: macrophage scavenger receptors and LDL receptor-related protein (LRP). Annu Rev Biochem 63, 601-637.
140. Lee, J., Chuang, T. H., Redecke, V., She, L., Pitha, P. M., Carson, D. A., et al. (2003). Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: activation of Toll-like receptor 7. Proc Natl Acad Sci U S A 100, 6646-6651.
141. Lee, S. H., Soyoola, E., Chanmugam, P., Hart, S., Sun, W., Zhong, H., et al. (1992). Selective expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide. J Biol Chem 267, 25934-25938.
142. Lemaitre, B., Nicolas, E., Michaut, L., Reichhart, J. M., & Hoffmann, J. A. (1996). The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 86, 973-983.
143. Lich, J. D., Williams, K. L., Moore, C. B., Arthur, J. C., Davis, B. K., Taxman, D. J., et al. (2007). Monarch-1 suppresses non-canonical NF-kappaB activation and p52-dependent chemokine expression in monocytes. J Immunol 178, 1256-1260.
144. Liu, X., Chauhan, V. S., Young, A. B., & Marriott, I. (2010). NOD2 mediates inflammatory responses of primary murine glia to Streptococcus pneumoniae. Glia 58, 839-847.
145. Liu, Y., Chen, G. Y., & Zheng, P. (2009). CD24-Siglec G/10 discriminates danger- from pathogen-associated molecular patterns. Trends Immunol 30, 557-561.
146. Lopez, A., Lorente, J. A., Steingrub, J., Bakker, J., McLuckie, A., Willatts, S., et al. (2004). Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med 32, 21-30.
147. Lotze, M. T., & Tracey, K. J. (2005). High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 5, 331-342.
148. Loving, C. L., Osorio, M., Kim, Y. G., Nunez, G., Hughes, M. A., & Merkel, T. J. (2009). Nod1/Nod2-mediated recognition plays a critical role in induction of adaptive immunity to anthrax after aerosol exposure. Infect Immun 77, 4529-4537.
149. Lucattelli, M., Cicko, S., Müller, T., Lommatzsch, M., De Cunto, G., Cardini, S., et al. (2011). P2X7 receptor signaling in the pathogenesis of smoke-induced lung inflammation and emphysema. Am J Respir Cell Mol Biol 44, 423-429.
150. Lundy, S. R., Dowling, R. L., Stevens, T. M., Kerr, J. S., Mackin, W. M., & Gans, K. R. (1990). Kinetics of phospholipase A2, arachidonic acid, and eicosanoid appearance in mouse zymosan peritonitis. J Immunol 144, 2671-2677.
151. Lynn, W. A., & Golenbock, D. T. (1992). Lipopolysaccharide antagonists. Immunol Today 13, 271-276.
152. Maclean, L. D., & Weil, M. H. (1956). Hypotension (shock) in dogs produced by Escherichia coli endotoxin. Circ Res 4, 546-556.
153. Maedler, K., Dharmadhikari, G., Schumann, D. M., & Storling, J. (2009). Interleukin-1 beta targeted therapy for type 2 diabetes. Expert Opin Biol Ther 9, 1177-1188.
154. Manukyan, M., Triantafilou, K., Triantafilou, M., Mackie, A., Nilsen, N., Espevik, T., et al. (2005). Binding of lipopeptide to CD14 induces physical proximity of CD14, TLR2 and TLR1. Eur J Immunol 35, 911-921.
155. Mariathasan, S., Weiss, D. S., Newton, K., McBride, J., O'Rourke, K., Roose-Girma, M., et al. (2006). Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 440, 228-232.
156. Marina-Garcia, N., Franchi, L., Kim, Y. G.,Miller, D.,McDonald, C., Boons, G. J., et al. (2008). Pannexin-1-mediated intracellular delivery of muramyl dipeptide induces caspase-1 activation via cryopyrin/NLRP3 independently of Nod2. J Immunol 180, 4050-4057.
157. Martinon, F., Petrilli, V., Mayor, A., Tardivel, A., & Tschopp, J. (2006). Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440, 237-241.
158. Masumoto, J., Yang, K., Varambally, S., Hasegawa, M., Tomlins, S. A., Qiu, S., et al. (2006). Nod1 acts as an intracellular receptor to stimulate chemokine production and neutrophil recruitment in vivo. J Exp Med 203, 203-213.
159. Matzinger, P. (1994). Tolerance, danger, and the extended family. Annu Rev Immunol 12, 991-1045.
160. McCloskey, R. V., Straube, R. C., Sanders, C., Smith, S. M., & Smith, C. R. (1994). Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group. Ann Intern Med 121, 1-5.
161. McDonald, C., Inohara, N., & Nunez, G. (2005). Peptidoglycan signaling in innate immunity and inflammatory disease. J Biol Chem 280, 20177-20180.
162. Medzhitov, R., Preston-Hurlburt, P., & Janeway, C. A., Jr. (1997). A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388, 394-397.
163. Merx, S., Neumaier,M.,Wagner,H., Kirschning, C. J., & Ahmad-Nejad, P. (2007). Characterization and investigation of single nucleotide polymorphisms and a novel TLR2 mutation in the human TLR2 gene. Hum Mol Genet 16, 1225-1232.
164. Mitchell, J. A., Fitzgerald, K. A., Coyle, A., Silverman, N., & Cartwright, N. (2006). TOLLing away in Brazil. Nat Immunol 7, 675-679.
165. Moreno, L., McMaster, S. K., Gatheral, T., Bailey, L. K., Harrington, L. S., Cartwright, N., et al. (2010). Nucleotide oligomerization domain 1 is a dominant pathway for NOS2 induction in vascular smooth muscle cells: comparison with Toll-like receptor 4 responses in macrophages. Br J Pharmacol 160, 1997-2007.
166. Moyer, C. F., Sajuthi, D., Tulli, H., & Williams, J. K. (1991). Synthesis of IL-1 alpha and IL-1 beta by arterial cells in atherosclerosis. Am J Pathol 138, 951-960.
167. Mullick, A. E., Tobias, P. S., & Curtiss, L. K. (2005). Modulation of atherosclerosis in mice by Toll-like receptor 2. J Clin Invest 115, 3149-3156.
168. Myhre, A. E., Aasen, A. O., Thiemermann, C., & Wang, J. E. (2006). Peptidoglycan-an endotoxin in its own right? Shock 25, 227-235.
169. Nadra, I., Mason, J. C., Philippidis, P., Florey, O., Smythe, C. D., McCarthy, G. M., et al. (2005). Proinflammatory activation of macrophages by basic calcium phosphate crystals via protein kinase C and MAP kinase pathways: a vicious cycle of inflammation and arterial calcification? Circ Res 96, 1248-1256.
170. Navab, M., Fogelman, A. M., Berliner, J. A., Territo, M. C., Demer, L. L., Frank, J. S., et al. (1995). Pathogenesis of atherosclerosis. Am J Cardiol 76, 18C-23C.
171. Nicholas, S. A., & Sumbayev, V. V. (2009). The involvement of hypoxia-inducible factor 1 alpha in Toll-like receptor 7/8-mediated inflammatory response. Cell Res 19(8), 973-983.
172. Nuotio, K., Isoviita, P. M., Saksi, J., Ijas, P., Pitkaniemi, J., Sonninen, R., et al. (2007). Adipophilin expression is increased in symptomatic carotid atherosclerosis: correlation with red blood cells and cholesterol crystals. Stroke 38, 1791-1798.
173. Ogura, Y., Bonen, D. K., Inohara, N., Nicolae, D. L., Chen, F. F., Ramos, R., et al. (2001a). A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411, 603-606.
174. Ogura, Y., Inohara, N., Benito, A., Chen, F. F., Yamaoka, S., & Nunez, G. (2001b). Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kappaB. J Biol Chem276, 4812-4818.
175. Ogus, A. C., Yoldas, B., Ozdemir, T., Uguz, A., Olcen, S., Keser, I., et al. (2004). The Arg753GLn polymorphism of the human Toll-like receptor 2 gene in tuberculosis disease. Eur Respir J 23, 219-223.
176. O'Neill, L. A., & Bowie, A. G. (2007). The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol 7, 353-364.
177. O'Neill, L. A., Bryant, C. E., & Doyle, S. L. (2009). Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer. Pharmacol Rev 61, 177-197.
178. Opitz, B., Eitel, J., Meixenberger, K., & Suttorp, N. (2009). Role of Toll-like receptors, NOD-like receptors and RIG-I-like receptors in endothelial cells and systemic infections. Thromb Haemost 102(6), 1103-1109.
179. Ott, S. J., El Mokhtari, N. E., Musfeldt, M., Hellmig, S., Freitag, S., Rehman, A., et al. (2006). Detection of diverse bacterial signatures in atherosclerotic lesions of patients with coronary heart disease. Circulation 113, 929-937.
180. Ozinsky, A., Underhill, D. M., Fontenot, J. D., Hajjar, A. M., Smith, K. D., Wilson, C. B., et al. (2000). The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between Toll-like receptors. Proc Natl Acad Sci U S A 97, 13766-13771.
181. Patel, T. A., Belcher, E., Warner, T. D., Harding, S. E., & Mitchell, J. A. (2007). Identification and characterization of a dysfunctional cardiac myocyte phenotype: role of bacteria, Toll-like receptors, and endothelin. Shock 28, 434-440.
182. Patel, M., Xu, D., Kewin, P., Choo-Kang, B., McSharry, C., Thomson, N. C., et al. (2005). TLR2 agonist ameliorates established allergic airway inflammation by promoting Th1 response and not via regulatory T cells. J Immunol 174, 7558-7563.
183. Paul-Clark, M., Del Soldato, P., Fiorucci, S., Flower, R. J., & Perretti, M. (2000). 21-NO-prednisolone is a novel nitric oxide-releasing derivative of prednisolone with enhanced anti-inflammatory properties. Br J Pharmacol 131, 1345-1354.
184. Paul-Clark, M. J., McMaster, S. K., Belcher, E., Sorrentino, R., Anandarajah, J., Fleet, M., et al. (2006). Differential effects of Gram-positive versus Gram-negative bacteria on NOSII and TNFalpha in macrophages: role of TLRs in synergy between the two. Br J Pharmacol 148, 1067-1075.
185. Paul-Clark, M., McMaster, S., Sorrentino, R., Sriskandan, S., Bailey, L., Moreno, L., et al. (2009a). Toll-like receptor 2 is essential for the sensing of oxidants during inflammation. Am J Respir Crit Care Med 179, 299-306.
186. Paul-Clark, M. J., McMaster, S. K., Sorrentino, R., Sriskandan, S., Bailey, L. K., Moreno, L., et al. (2009b). Toll-like receptor 2 is essential for the sensing of oxidants during inflammation. Am J Respir Crit Care Med 179, 299-306.
187. Pelegrin, P., Barroso-Gutierrez, C., & Surprenant, A. (2008). P2X7 receptor differentially couples to distinct release pathways for IL-1beta in mouse macrophage. J Immunol 180, 7147-7157.
188. Pelegrin, P., & Surprenant, A. (2006). Pannexin-1 mediates large pore formation and interleukin-1beta release by the ATP-gated P2X7 receptor. EMBO J 25, 5071-5082.
189. Perretti, M., Ahluwalia, A., Harris, J. G., Goulding, N. J., & Flower, R. J. (1993). Lipocortin-1 fragments inhibit neutrophil accumulation and neutrophil-dependent edema in the mouse. A qualitative comparison with an anti-CD11b monoclonal antibody. J Immunol 151, 4306-4314.
190. Petricevic, B., Wessner, B., Sachet, M., Vrbanec, D., Spittler, A., & Bergmann, M. (2009). CL097, a TLR7/8 ligand, inhibits TLR-4-dependent activation of IRAK-M and BCL-3 expression. Shock 32, 484-490.
191. Petros, A., Bennett, D., & Vallance, P. (1991). Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock. Lancet 338, 1557-1558.
192. Poltorak, A., He, X., Smirnova, I., Liu, M. Y., Van Huffel, C., Du, X., et al. (1998). Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282, 2085-2088.
193. Price, S., Evans, T.W., &Mitchell, J. A. (2002).Nitric oxide supports atrial function in sepsis: relevance to side effects of inhibitors in shock. Eur J Pharmacol 449, 279-285.
194. Price, S., Mitchell, J. A., Anning, P. B., & Evans, T. W. (2003). Type II nitric oxide synthase activity is cardio-protective in experimental sepsis. Eur J Pharmacol 472, 111-118.
195. Qureshi, N., Takayama, K., & Ribi, E. (1982). Purification and structural determination of nontoxic lipid A obtained from the lipopolysaccharide of Salmonella typhimurium. J Biol Chem 257, 11808-11815.
196. Raetz, C. R. (1990). Biochemistry of endotoxins. Annu Rev Biochem 59, 129-170.
197. Raetz, C. R., Garrett, T. A., Reynolds, C. M., Shaw, W. A., Moore, J. D., Smith, D. C., Jr., et al. (2006). Kdo2-lipid A of Escherichia coli, a defined endotoxin that activates macrophages via TLR-4. J Lipid Res 47, 1097-1111.
198. Rallabhandi, P., Awomoyi, A., Thomas, K. E., Phalipon, A., Fujimoto, Y., Fukase, K., et al. (2008). Differential activation of human TLR4 by Escherichia coli and Shigella flexneri 2a lipopolysaccharide: combined effects of lipid A acylation state and TLR4 polymorphisms on signaling. J Immunol 180, 1139-1147.
199. Ritter, M., Mennerich, D., Weith, A., & Seither, P. (2005). Characterization of Toll-like receptors in primary lung epithelial cells: strong impact of the TLR3 ligand poly(I:C) on the regulation of Toll-like receptors, adaptor proteins and inflammatory response. J Inflamm (Lond) 2, 16.
200. Rock, F. L., Hardiman, G., Timans, J. C., Kastelein, R. A., & Bazan, J. F. (1998). A family of human receptors structurally related to Drosophila Toll. Proc Natl Acad Sci U S A 95, 588-593.
201. Rodrigue-Gervais, I. G., & Saleh, M. (2010). Genetics of inflammasome-associated disorders: a lesson in the guiding principals of inflammasome function. Eur J Immunol 40, 643-648.
202. Ross, R. (1999). Atherosclerosis is an inflammatory disease. Am Heart J 138, S419-S420.
203. Rutschmann, S., Jung, A. C., Hetru, C., Reichhart, J. M., Hoffmann, J. A., & Ferrandon, D. (2000a). The Rel protein DIF mediates the antifungal but not the antibacterial host defense in Drosophila. Immunity 12, 569-580.
204. Rutschmann, S., Jung, A. C., Zhou, R., Silverman, N., Hoffmann, J. A., & Ferrandon, D. (2000b). Role of Drosophila IKK gamma in a Toll-independent antibacterial immune response. Nat Immunol 1, 342-347.
205. Sabbah, A., Chang, T. H., Harnack, R., Frohlich, V., Tominaga, K., Dube, P. H., et al. (2009). Activation of innate immune antiviral responses by Nod2. Nat Immunol 10, 1073-1080.
206. Sato, K., Yang, X. L., Yudate, T., Chung, J. S., Wu, J., Luby-Phelps, K., et al. (2006). Dectin-2 is a pattern recognition receptor for fungi that couples with the Fc receptor gamma chain to induce innate immune responses. J Biol Chem 281, 38854-38866.
207. Satoh, M., Ishikawa, Y., Minami, Y., Takahashi, Y., & Nakamura, M. (2008). Role of Toll like receptor signaling pathway in ischemic coronary artery disease. Front Biosci 13, 6708-6715.
208. Schaefer, L., Babelova, A., Kiss, E., Hausser, H. J., Baliova, M., Krzyzankova, M., et al. (2005). The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. J Clin Invest 115, 2223-2233.
209. Scheibner, K. A., Lutz, M. A., Boodoo, S., Fenton, M. J., Powell, J. D., & Horton, M. R. (2006). Hyaluronan fragments act as an endogenous danger signal by engaging TLR2. J Immunol 177, 1272-1281.
210. Schertzer, J. D., Tamrakar, A. K., Magalhaes, J. G., Pereira, S., Bilan, P. J., Fullerton, M. D., et al. (2011). NOD1 activators link innate immunity to insulin resistance. Diabetes 60, 2206-2215.
211. Schon, M. P., & Schon, M. (2008). TLR7 and TLR8 as targets in cancer therapy. Oncogene 27, 190-199.
212. Schroder, N. W., Diterich, I., Zinke, A., Eckert, J., Draing, C., von Baehr, V., et al. (2005). Heterozygous Arg753Gln polymorphism of human TLR-2 impairs immune activation by Borrelia burgdorferi and protects from late stage Lyme disease. J Immunol 175, 2534-2540.
213. Schroder, N. W., Heine, H., Alexander, C., Manukyan, M., Eckert, J., Hamann, L., et al. (2004). Lipopolysaccharide binding protein binds to triacylated and diacylated lipopeptides and mediates innate immune responses. J Immunol 173, 2683-2691.
214. Schroder, N. W., & Schumann, R. R. (2005). Single nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious disease. Lancet Infect Dis 5, 156-164.
215. Schumann, R. R. (2011). Old and new findings on lipopolysaccharide- binding protein: a soluble pattern-recognition molecule. Biochem Soc Trans 39, 989-993.
216. Schumann, R. R., Leong, S. R., Flaggs, G. W., Gray, P. W., Wright, S. D., Mathison, J. C., et al. (1990). Structure and function of lipopolysaccharide binding protein. Science 249, 1429-1431.
217. Segal, B. M., Chang, J. T., & Shevach, E. M. (2000). CpG oligonucleotides are potent adjuvants for the activation of autoreactive encephalitogenic T cells in vivo. J Immunol 164, 5683-5688.
218. Seong, S. Y., & Matzinger, P. (2004). Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. Nat Rev Immunol 4, 469-478.
219. Sessa, R., Nicoletti, M., Di Pietro, M., Schiavoni, G., Santino, I., Zagaglia, C., et al. (2009). Chlamydia pneumoniae and atherosclerosis: current state and future prospectives. Int J Immunopathol Pharmacol 22, 9-14.
220. Seyberth, T., Voss, S., Brock, R., Wiesmuller, K. H., & Jung, G. (2006). Lipolanthionine peptides act as inhibitors of TLR2-mediated IL-8 secretion. Synthesis and structure-activity relationships. J Med Chem 49, 1754-1765.
221. Sharma, K., Kumar, C., Keri, G., Breitkopf, S. B., Oppermann, F. S., & Daub, H. (2010). Quantitative analysis of kinase-proximal signaling in lipopolysaccharide-induced innate immune response. J Proteome Res 9(5), 2539-2549.
222. Shaw, P. J., Lamkanfi, M., & Kanneganti, T. D. (2010). NOD-like receptor (NLR) signaling beyond the inflammasome. Eur J Immunol 40, 624-627.
223. Shiina, M., Kobayashi, K., Satoh, H., Niitsuma, H., Ueno, Y., & Shimosegawa, T. (2004). Ribavirin upregulates interleukin-12 receptor and induces T cell differentiation towards type 1 in chronic hepatitis C. J Gastroenterol Hepatol 19, 558-564.
224. Shimazu, R., Akashi, S., Ogata, H., Nagai, Y., Fukudome, K.,Miyake, K., et al. (1999).MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med 189, 1777-1782.
225. Shojaei, H., Oberg, H. H., Juricke, M., Marischen, L., Kunz, M., Mundhenke, C., et al. (2009). Toll-like receptors 3 and 7 agonists enhance tumor cell lysis by human gammadelta T cells. Cancer Res 69, 8710-8717.
226. Sidky, Y. A., Borden, E. C., Weeks, C. E., Reiter, M. J., Hatcher, J. F., & Bryan, G. T. (1992). Inhibition ofmurine tumor growth by an interferon-inducing imidazoquinolinamine. Cancer Res 52, 3528-3533.
227. Skidmore, B. J., Chiller, J. M., Morrison, D. C., & Weigle, W. O. (1975). Immunologic properties of bacterial lipopolysaccharide (LPS): correlation between the mitogenic, adjuvant, and immunogenic activities. J Immunol 114, 770-775.
228. Smirnova, I., Mann, N., Dols, A., Derkx, H. H., Hibberd, M. L., Levin, M., et al. (2003). Assay of locus-specific genetic load implicates rare Toll-like receptor 4 mutations in meningococcal susceptibility. Proc Natl Acad Sci U S A 100, 6075-6080.
229. Spiller, S., Elson, G., Ferstl, R., Dreher, S., Mueller, T., Freudenberg, M., et al. (2008). TLR4-induced IFN-gamma production increases TLR2 sensitivity and drives Gram-negative sepsis in mice. J Exp Med 205, 1747-1754.
230. Spyvee, M. R., Zhang, H., Hawkins, L. D., & Chow, J. C. (2005). Toll-like receptor 2 antagonists. Part 1: preliminary SAR investigation of novel synthetic phospholipids. Bioorg Med Chem Lett 15, 5494-5498.
231. Stahl, G. L., Fletcher, M. P., Amsterdam, E. A., & Longhurst, J. C. (1991). Role of granulocytes and C5a in myocardial response to zymosan-activated serum. Am J Physiol 261, H29-H37.
232. Staniland, A. A., Clark, A. K.,Wodarski, R., Sasso, O., Maione, F., D'Acquisto, F., et al. (2010). Reduced inflammatory and neuropathic pain and decreased spinalmicroglial response in fractalkine receptor (CX3CR1) knockout mice. J Neurochem 114(4), 1143-1157.
233. Stockfleth, E., Trefzer, U., Garcia-Bartels, C., Wegner, T., Schmook, T., & Sterry, W. (2003). The use of Toll-like receptor-7 agonist in the treatment of basal cell carcinoma: an overview. Br J Dermatol 149(Suppl. 66), 53-56.
234. Streblow, D. N., Orloff, S. L., & Nelson, J. A. (2001). Do pathogens accelerate atherosclerosis? J Nutr 131, 2798S-2804S.
235. Stuehr, D. J., & Marletta, M. A. (1985). Mammalian nitrate biosynthesis: mouse macrophages produce nitrite and nitrate in response to Escherichia coli lipopolysaccharide. Proc Natl Acad Sci U S A 82, 7738-7742.
236. Stutz, A., Golenbock, D. T., & Latz, E. (2009). Inflammasomes: too big to miss. J Clin Invest 119, 3502-3511.
237. Sugai, T., Mori, M., Nakazawa, M., Ichino, M., Naruto, T., Kobayashi, N., et al. (2005). A CpG-containing oligodeoxynucleotide as an efficient adjuvant counterbalancing the Th1/Th2 immune response in diphtheria-tetanus-pertussis vaccine. Vaccine 23, 5450-5456.
238. Szabo, C., Mitchell, J. A., Thiemermann, C., & Vane, J. R. (1993). Nitric oxide-mediated hyporeactivity to noradrenaline precedes the induction of nitric oxide synthase in endotoxin shock. Br J Pharmacol 108, 786-792.
239. Tada, H., Aiba, S., Shibata, K., Ohteki, T., & Takada, H. (2005). Synergistic effect of Nod1 and Nod2 agonists with Toll-like receptor agonists on human dendritic cells to generate interleukin-12 and T helper type 1 cells. Infect Immun 73, 7967-7976.
240. Taguchi, T., Mitcham, J. L., Dower, S. K., Sims, J. E., & Testa, J. R. (1996). Chromosomal localization of TIL, a gene encoding a protein related to the Drosophila transmembrane receptor Toll, to human chromosome 4p14. Genomics 32, 486-488.
241. Takeda, K., & Akira, S. (2007). Toll-like receptors. Curr Protoc Immunol (Chapter 14, Unit 14 12). PMID: 18432983.
242. Takeda, K., Kaisho, T., & Akira, S. (2003). Toll-like receptors. Annu Rev Immunol 21, 335-376.
243. Takeuchi, O., Hoshino, K., Kawai, T., Sanjo, H., Takada, H., Ogawa, T., et al. (1999a). Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity 11, 443-451.
244. Takeuchi, O., Kawai, T., Sanjo, H., Copeland, N. G., Gilbert, D. J., Jenkins, N. A., et al. (1999b). TLR6: a novel member of an expanding Toll-like receptor family. Gene 231, 59-65.
245. Tenger, C., Sundborger, A., Jawien, J., & Zhou, X. (2005). IL-18 accelerates atherosclerosis accompanied by elevation of IFN-gamma and CXCL16 expression independently of T cells. Arterioscler Thromb Vasc Biol 25, 791-796.
246. Termeer, C., Benedix, F., Sleeman, J., Fieber, C., Voith, U., Ahrens, T., et al. (2002). Oligosaccharides of hyaluronan activate dendritic cells via Toll-like receptor 4. J Exp Med 195, 99-111.
247. Tesar, B. M., Jiang, D., Liang, J., Palmer, S. M., Noble, P. W., & Goldstein, D. R. (2006). The role of hyaluronan degradation products as innate alloimmune agonists. Am J Transplant 6, 2622-2635.
248. Ting, J. P., Lovering, R. C., Alnemri, E. S., Bertin, J., Boss, J. M., Davis, B. K., et al. (2008). The NLR gene family: a standard nomenclature. Immunity 28, 285-287.
249. Tiret, L., Godefroy, T., Lubos, E., Nicaud, V., Tregouet, D. A., Barbaux, S., et al. (2005). Genetic analysis of the interleukin-18 system highlights the role of the interleukin-18 gene in cardiovascular disease. Circulation 112, 643-650.
250. Tjarnlund, A., Guirado, E., Julian, E., Cardona, P. J., & Fernandez, C. (2006). Determinant role for Toll-like receptor signalling in acute mycobacterial infection in the respiratory tract. Microbes Infect 8, 1790-1800.
251. Tobias, P. S., Soldau, K., & Ulevitch, R. J. (1989). Identification of a lipid A binding site in the acute phase reactant lipopolysaccharide binding protein. J Biol Chem 264, 10867-10871.
252. Toshchakov, V. Y., Fenton, M. J., & Vogel, S. N. (2007). Cutting edge: differential inhibition of TLR signaling pathways by cell-permeable peptides representing BB loops of TLRs. J Immunol 178, 2655-2660.
253. Toshchakov, V., Jones, B. W., Perera, P. Y., Thomas, K., Cody, M. J., Zhang, S., et al. (2002). TLR4, but not TLR2, mediates IFN-beta-induced STAT1alpha/beta-dependent gene expression in macrophages. Nat Immunol 3, 392-398.
254. Toshchakov, V. Y., & Vogel, S. N. (2007). Cell-penetrating TIR BB loop decoy peptides a novel class of TLR signaling inhibitors and a tool to study topology of TIR-TIR interactions. Expert Opin Biol Ther 7, 1035-1050.
255. Tracey, K. J., Lowry, S. F., & Cerami, A. (1988). Cachectin/TNF mediates the pathophysiological effects of bacterial endotoxin/ lipopolysaccharide (LPS). Prog Clin Biol Res 272, 77-88.
256. Trumpfheller, C., Caskey, M., Nchinda, G., Longhi, M. P., Mizenina, O., Huang, Y., et al. (2008). The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine. Proc Natl Acad Sci U S A 105, 2574-2579.
257. Tsan, M. F., & Gao, B. (2004). Endogenous ligands of Toll-like receptors. J Leukoc Biol 76, 514-519.
258. Tsui, F. W., Xi, N., Rohekar, S., Riarh, R., Bilotta, R., Tsui, H. W., et al. (2008). Toll-like receptor 2 variants are associated with acute reactive arthritis. Arthritis Rheum 58, 3436-3438.
259. Turnbach, M. E., & Randich, A. (2002). The role of spinal neurokinin-1 and glutamate receptors in hyperalgesia and allodynia induced by prostaglandin E(2) or zymosan in the rat. Pain 97, 127-137.
260. Uehara, A., Fujimoto, Y., Fukase, K., & Takada, H. (2007). Various human epithelial cells express functional Toll-like receptors, NOD1 and NOD2 to produce anti-microbial peptides, but not proinflammatory cytokines. Mol Immunol 44, 3100-3111.
261. van Heel, D. A., Ghosh, S., Butler, M., Hunt, K., Foxwell, B. M., Mengin-Lecreulx, D., & Playford, R. J. (2005). Synergistic enhancement of Toll-like receptor responses by NOD1 activation. Eur J Immunol 35(8), 2471-2476.
262. Verri, W. A., Jr., Cunha, T. M., Parada, C. A., Poole, S., Cunha, F. Q., & Ferreira, S. H. (2006). Hypernociceptive role of cytokines and chemokines: targets for analgesic drug development? Pharmacol Ther 112, 116-138.
263. Viala, J., Chaput, C., Boneca, I. G., Cardona, A., Girardin, S. E., Moran, A. P., et al. (2004). Nod1 responds to peptidoglycan delivered by the Helicobacter pylori cag pathogenicity island. Nat Immunol 5, 1166-1174.
264. Vijay-Kumar, M., Sanders, C. J., Taylor, R. T., Kumar, A., Aitken, J. D., Sitaraman, S. V., et al. (2007). Deletion of TLR5 results in spontaneous colitis in mice. J Clin Invest 117, 3909-3921.
265. Viriyakosol, S., Tobias, P. S., Kitchens, R. L., & Kirkland, T. N. (2001). MD-2 binds to bacterial lipopolysaccharide. J Biol Chem 276, 38044-38051.
266. Vollmer, J., Rankin, R., Hartmann, H., Jurk, M., Samulowitz, U., Wader, T., et al. (2004). Immunopharmacology of CpG oligodeoxynucleotides and ribavirin. Antimicrob Agents Chemother 48, 2314-2317.
267. Voronov, E., Dayan, M., Zinger, H., Gayvoronsky, L., Lin, J. P., Iwakura, Y., et al. (2006). IL-1 beta-deficient mice are resistant to induction of experimental SLE. Eur Cytokine Netw 17, 109-116.
268. Wandstrat, A., & Wakeland, E. (2001). The genetics of complex autoimmune diseases: non-MHC susceptibility genes. Nat Immunol 2, 802-809.
269. Wang, J. E., Dahle, M. K., McDonald, M., Foster, S. J., Aasen, A. O., & Thiemermann, C. (2003). Peptidoglycan and lipoteichoic acid in gram-positive bacterial sepsis: receptors, signal transduction, biological effects, and synergism. Shock 20, 402-414.
270. Warshakoon, H. J., Hood, J. D., Kimbrell, M. R., Malladi, S., Wu, W. Y., Shukla, N. M., et al. (2009). Potential adjuvantic properties of innate immune stimuli. Hum Vaccin 5, 381-394.
271. Weeratna, R. D., McCluskie, M. J., Xu, Y., & Davis, H. L. (2000). CpG DNA induces stronger immune responses with less toxicity than other adjuvants. Vaccine 18, 1755-1762.
272. Wintergerst, E., Manz-Keinke, H., Plattner, H., & Schlepper-Schafer, J. (1989). The interaction of a lung surfactant protein (SP-A) with macrophages is mannose dependent. Eur J Cell Biol 50, 291-298.
273. Wright, S. D., Ramos, R. A., Tobias, P. S., Ulevitch, R. J., & Mathison, J. C. (1990). CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 249, 1431-1433.
274. Wu, C. C., Croxtall, J. D., Perretti, M., Bryant, C. E., Thiemermann, C., Flower, R. J., et al. (1995). Lipocortin 1 mediates the inhibition by dexamethasone of the induction by endotoxin of nitric oxide synthase in the rat. Proc Natl Acad Sci U S A 92, 3473-3477.
275. Wu, J. Z., Lin, C. C., & Hong, Z. (2003). Ribavirin, viramidine and adenosine-deaminase-catalysed drug activation: implication for nucleoside prodrug design. J Antimicrob Chemother 52, 543-546.
276. Yamamoto, M., Sato, S., Hemmi, H., Sanjo, H., Uematsu, S., Kaisho, T., et al. (2002). Essential role for TIRAP in activation of the signalling cascade shared by TLR2 and TLR4. Nature 420, 324-329.
277. Yang, I. A., Holz, O., Jorres, R. A., Magnussen, H., Barton, S. J., Rodriguez, S., et al. (2005). Association of tumor necrosis factor-alpha polymorphisms and ozone-induced change in lung function. Am J Respir Crit Care Med 171, 171-176.
278. Yarovinsky, F., Zhang, D., Andersen, J. F., Bannenberg, G. L., Serhan, C. N., Hayden, M. S., et al. (2005). TLR11 activation of dendritic cells by a protozoan profilin-like protein. Science 308, 1626-1629.
279. Yokota, Y., Mine, Y., Wakai, Y., Watanabe, Y., Nishida, M., Goto, S., et al. (1983). Immunoactive peptides, FK-156 and FK-565. II. Restoration of host resistance to microbial infection in immunosuppressed mice. J Antibiot (Tokyo) 36, 1051-1058.
280. Yokota, K., Takashima, A., Bergstresser, P. R., & Ariizumi, K. (2001). Identification of a human homologue of the dendritic cell-associated C-type lectin-1, dectin-1. Gene 272, 51-60.
281. Yoshimura, A., Kaneko, T., Kato, Y., Golenbock, D. T., & Hara, Y. (2002). Lipopolysaccharides from periodontopathic bacteria Porphyromonas gingivalis and Capnocytophaga ochracea are antagonists for human Toll-like receptor 4. Infect Immun 70, 218-225.
282. Yu, J. E., Knight, A. K., Radigan, L., Marron, T. U., Zhang, L., Sanchez-Ramon, S., et al. (2009). Toll-like receptor 7 and 9 defects in common variable immunodeficiency. J Allergy Clin Immunol 124, 349-356 (356 e341-343).
283. Zahringer, U., Lindner, B., Inamura, S.,Heine,H., & Alexander, C. (2008). TLR2-promiscuous or specific? A critical re-evaluation of a receptor expressing apparent broad specificity. Immunobiology 213, 205-224.
284. Zelensky, A. N., & Gready, J. E. (2005). The C-type lectin-like domain superfamily. FEBS J 272, 6179-6217.
285. Zhang, G., & Ghosh, S. (2002). Negative regulation of Toll-like receptor-mediated signaling by Tollip. J Biol Chem 277, 7059-7065.
286. Zhang, Y., Lee, A. S., Shameli, A., Geng, X., Finegood, D., Santamaria, P., et al. (2010). TLR9 blockade inhibits activation of diabetogenic CD8+ T cells and delays autoimmune diabetes. J Immunol 184, 5645-5653.
287. Zhang, X., Shan, P., Jiang, G., Cohn, L., & Lee, P. J. (2006). Toll-like receptor 4 deficiency causes pulmonary emphysema. J Clin Invest 116, 3050-3059.
288. Zhao, L., Hu, P., Zhou, Y., Purohit, J., & Hwang, D. (2011). NOD1 activation induces proinflammatory gene expression and insulin resistance in 3T3-L1 adipocytes. Am J Physiol Endocrinol Metab 301, E587-E598.
289. Zhou, R., Tardivel, A., Thorens, B., Choi, I., & Tschopp, J. (2010). Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol 11, 136-140.
290. Zhou, Z., Yamamoto, Y., Sugai, F., Yoshida, K., Kishima, Y., Sumi, H., et al. (2004). Hepatoma- derived growth factor is a neurotrophic factor harbored in the nucleus. J Biol Chem 279, 27320-27326.
291. Ziegler, E. J., Fisher, C. J., Jr., Sprung, C. L., Straube, R. C., Sadoff, J. C., Foulke, G. E., et al. (1991). Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med 324, 429-436.